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VIRAL HEPATITIS
Oxidized Low-Density Lipoprotein Inhibits Hepatitis C
Virus Cell Entry in Human Hepatoma Cells
Thomas von Hahn,1 Brett D. Lindenbach,1 Agne`s Boullier,2 Oswald Quehenberger,2 Matthew Paulson,1
Charles M. Rice,1 and Jane A. McKeating1
Cell entry of hepatitis C virus, pseudoparticles (HCVpp) and cell culture grown virus (HCVcc),
requires the interaction of viral glycoproteins with CD81 and other as yet unknown cellular
factors. One of these is likely to be the scavenger receptor class B type I (SR-BI). To further
understand the role of SR-BI, we examined the effect of SR-BI ligands on HCVpp and HCVcc
infectivity. Oxidized low-density lipoprotein (oxLDL), but not native LDL, potently inhibited
HCVpp and HCVcc cell entry. Pseudoparticles bearing unrelated viral glycoproteins or bovine
viral diarrhea virus were not affected. A dose-dependent inhibition was observed for HCVpp
bearing diverse viral glycoproteins with an approximate IC50 of 1.5 !g/mL apolipoprotein
content, which iswithin the range of oxLDL reported to be present in humanplasma.The ability
of lipoprotein components to bind to target cells associated with their antiviral activity, suggest-
ing a mechanism of action which targets a cell surface receptor critical for HCV infection of the
host cell. However, binding of soluble E2 to SR-BI or CD81 was not affected by oxLDL,
suggesting that oxLDL does not act as a simple receptor blocker. At the same time, oxLDL
incubation altered the biophysical properties of HCVpp, suggesting a ternary interaction of
oxLDL with both virus and target cells. In conclusion, the SR-BI ligand oxLDL is a potent cell
entry inhibitor for a broad range ofHCV strains in vitro. These findings suggest that SR-BI is an
essential component of the cellular HCV receptor complex. (HEPATOLOGY 2006;43:932-942.)
See Editorial on Page 903
Over 170 million individuals worldwide are in-fected with hepatitis C virus (HCV), a leadingcause of chronic hepatitis, cirrhosis, and hepa-
tocellular carcinoma. Infectious HCV purified from
plasma has been observed to complex low-density li-
poprotein (LDL), very low-density lipoprotein (VLDL),
and high-density lipoprotein (HDL).1-4 This association
may account for the low buoyant density of HCV RNA
containing particles in human plasma andmay be relevant
to the infectivity of HCV in vivo.1,5,6 Interestingly, recent
reports of cell culture–grown HCV (HCVcc) have found
a similar low buoyant density of infectious particles.7-9
HCV pseudoparticle (HCVpp)10,11 and HCVcc entry
into permissive cells is mediated through an interaction of
the viral encoded glycoproteins E1 and E2 with specific
cell surface–expressed receptors that include CD8112,13
and possibly scavenger receptor class B type I (SR-BI).14,15
CD81 is critical for HCVpp and HCVcc infection, but
CD81 expression alone is insufficient to render a cell per-
missive for HCVpp entry.7-11,15,16 A role for SR-BI in
HCVpp entry11,17 is supported by the observation that
HDL enhances HCVpp infectivity in an SR-BI–depen-
dent manner.18,19 However, whether this molecule plays
an essential or facilitating role awaits clarification.
SR-BI is a member of the scavenger receptor family
that is most highly expressed in the liver and steroidogenic
tissues (see Boullier et al.20 for review). Binding of HDL
to SR-BI results in either the selective uptake of cho-
lesteryl esters from HDL into the plasma membrane21 or
endocytosis of receptor-ligand complexes.22,23 Like most
scavenger receptors, SR-BI recognizes a wide range of li-
gands that include native HDL, LDL, and VLDL, as well
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as various chemically modified HDL and LDL spe-
cies.24-27 At least two distinct ligand-binding sites have
been reported to exist on the SR-BI molecule.23,28 To
further understand the role of SR-BI in HCV–cell entry,
we investigated the effects of SR-BI ligands on viral infec-
tivity. We found that oxidized LDL (oxLDL), a high-
affinity ligand of SR-BI,26 potently inhibits HCVpp and
HCVcc infection, supporting a critical role for SR-BI in
HCV entry and offering a potential target for therapeutic
intervention.
Materials and Methods
Cells and Reagents. 293T, Hep3B, Huh-7, Huh-7.5,
PLC/PRF5 and HepG2/CD81 cells were maintained in
Dulbecco’s modified Eagle medium (DMEM) with 10%
fetal bovine serum (FBS). Chinese hamster ovary (CHO)
cells were maintained in DMEM/F-12 with 10% FBS.
HepG2/CD81 cells were generated as previously report-
ed16 and grown on collagen-coated plastic. Lipoprotein-
deficient serum was purchased from Sigma (St. Louis,
MO).
Lipoproteins. LDL (1.019-1.063 g/mL) and HDL
(1.063-1.21 g/mL) were isolated from normolipidemic
human plasma via ultracentrifugation29 and dialyzed
against phosphate-buffered saline containing 0.3 mmol/L
EDTA. Lipoproteins were oxidized via incubation of 100
!g/mL native lipoproteins with 10!mol/LCuSO4 for 18
hours at 37°C. The degree of oxidation was determined
by measuring the amount of thiobarbituric acid–reactive
substances. Butylated hydroxytoluene (20 !mol/L) and
EDTA (0.1 mmol/L) were added to prevent further oxi-
dation. Na125I (2,000 Ci/mmol) for labeling oxLDL30
was obtained from ICN (Costa Mesa, CA). Apolipopro-
teins were isolated from lipoproteins by extracting lipids
with ice-cold methanol/chloroform (1:1, v/v) as previ-
ously described.31 The residual protein was washed with
water/acetone and solubilized in octylglucoside (octylglu-
coside/protein ! 30:1, w/w), and the detergent was re-
moved by way of dialysis. The apolipoprotein B of native
LDLwas not prepared, because it cannot be resolubilized.
The lipids from native and oxidized lipoproteins were
isolated as described previously,32 and their phospholipid
concentration was determined via phosphorus assay.33
Lipoprotein Cell-Binding Assay. To determine the
binding affinity of oxLDL toHep3B, cells were incubated
with various concentrations of 125I-oxLDL for 5 hours at
37°C in the presence or absence of a 30-fold excess of
unlabelled oxLDL. Cells were washed extensively and
lysed with 0.2 N NaOH. Aliquots were taken to measure
protein content and cell-associated "-radiation. Specific
binding was calculated as total binding minus nonspecific
binding in the presence of an excess of unlabeled oxLDL.
In the competition assays, 125I-oxLDLwas added with the
various unlabeled competitors for 5 hours at 37°C. Bind-
ing was then analyzed as described above.
RNA Interference. SMARTpool silencing RNAs
were purchased from Dharmacon (Lafayette, CO) and
transfected into Hep3B cells using Lipofectamine 2000
(Invitrogen, Carlsbad, CA). Silencing efficiency was as-
sessed via flow cytometry, and infection experiments were
performed 48 and 72 hours after transfection. An irrele-
vant small interfering RNA (siRNA) with low homology
to any human sequence was used as a negative control.
sE2 Cell-Binding Assay. CHOs were transduced
with CD81, CD9, and SR-BI using the pTRIP lentiviral
expression system. Transgene expression was confirmed
via fluorescence-activated cell sorting using antibodies
1.3.3.22 (Santa Cruz Biotechnology, Santa Cruz, CA),
anti-CD9 (Ancell, Bayport, MN), and anti–Cla-1 (BD,
Franklin Lakes, NJ) against CD81, CD9, and SR-BI,
respectively. Genotype 1a soluble E2 (sE2) containing
residues 384 to 661 was generated and its binding to cells
was detectedwith rat anti-E2monoclonal antibodies 9/75
and 7/59 as previously described.12,34
HCVpp Generation and Infection. HCVpp were
generated as previously described.10 Briefly using Lipo-
fectamine 293T cells were cotransfected with the enve-
lope-deficient HIV genome pNL4-3.Luc.R".E" and a
plasmid expressing any of the following viral glycopro-
teins: HCV strains H (genotype 1a), H77 (1a), OH8
(1b), or Con1 (1b); murine leukemia virus (MLV); vesic-
ular stomatitis virus G protein (VSV-G); or an empty
vector (“no envelope”). Medium was replaced with
DMEM/3% FBS after 6 hours. Supernatants were col-
lected after 48 hours and clarified via centrifugation. For
infection experiments, supernatants were diluted in
DMEM/3% FBS with 4 !g/mL polybrene with or with-
out the desired lipoprotein species. The mixture was in-
cubated at 37°C for 1 hour before being applied to the
target cells for 4 to 6 hours. Pseudoparticles were re-
moved, and the cells were incubated for a further 72
hours. Cells were lysed with 40 !L Cell Culture Lysis
Reagent (Promega, Madison, WI), and infection was
measured by quantifying the expression of the luciferase
reporter using 50 !L luciferase substrate (Promega) and a
Centro LB960 luminometer (Berthold Technologies,
Bad Wildbad, Germany).
Sedimentation Velocity Centrifugation Over Su-
crose Gradients. HCVpp containing supernatants were
loaded onto linear sucrose gradients (5%-20% w/v, in
TRIS-buffered saline) formed on a GradientMaster (Bio-
comp Inc., FrederictonNew Brunswick, Canada) accord-
ing to the manufacturer’s instructions. Samples were
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centrifuged in an SW41 rotor at 35,000 rpm for 20 min-
utes at 4°C. Fractions were collected from the top of the
gradient.
p24 ELISA. Pseudoparticles were inactivated with
1% Empigen and subsequent incubation at 56°C for 30
minutes. Commercially available capture anti-p24, re-
combinant HIV-1 p24 standard (Aalto Bio Reagents,
Dublin, Ireland), AP-conjugated anti-p24 (Cliniqa, Fall-
brook, CA), and AMPAK AP-substrate system (DakoCy-
tomation, Carpinteria, CA) were used according the
Aalto Bio Reagents protocol (www.aaltobioreagents.ie/
datasheet/protocol%201.pdf).
HCVcc Infection and NS5A Immunostaining. In-
fectious HCV J6/JFH particles were generated as previ-
ously described.7 Briefly, RNA was transcribed in vitro
from a chimeric full-length J6/JFH (both genotype 2a)
genome and electroporated into Huh-7.5 cells. After 72
hours, supernatants were collected, filtered, and applied
to naı¨ve Huh-7.5 target cells in the presence or absence of
human lipoproteins. Successful infection was detected 48
hours after infection via methanol fixation and staining
for NS5A antigen using a mouse monoclonal anti-NS5A
primary and HRP-conjugated anti–mouse immunoglob-
ulin G secondary antibody. Fifty percent tissue culture
infectious dose values were determined via limiting dilu-
tion assay.7,35
Statistical Analysis. All P values were determined
with the unpaired t test using Prism4 (GraphPad Soft-
ware, San Diego, CA). Error bars indicate the SD of du-
plicate experiments.
Results
OxLDL Inhibits HCVpp Infectivity. We evaluated
the effect of SR-BI ligands on HCVpp (clone H77) infec-
tion of Hep3B cells. Incubation of HCVpp with oxLDL
(at 10 !g/mL apolipoprotein content), but not native
LDL, reduced infectivity (as measured by expression of
the luciferase reporter) by more than 100-fold, whereas
VSV-Gpp and MLVpp were only modestly affected (less
than threefold in several independent experiments) (Figs.
1A, 2B). The copper-containing buffer in which oxLDL
was generated alone or mixed with native LDL had no
effect on HCVpp infectivity (not shown). The inhibition
was dose-dependent, with a half-maximal effect at 1.5
!g/mL (Fig. 1B). To rule out interference by bovine li-
Fig. 1. HDL enhancement and oxLDL inhibi-
tion of HCVpp infectivity. (A) Effect of native
LDL, native HDL, and oxLDL (10 !g/mL) on
HCVpp and VSVGpp infection of Hep3B cells.
(B) Dose response curve for oxLDL inhibition of
HCVpp infectivity. (C) Effect of oxLDL and native
HDL (10 !g/mL) on HCVpp generated and
used for infection in DMEM with either 3% FBS
or 3% lipoprotein-deficient serum. (D) Effect of
oxLDL on HCVpp infectivity in the presence of
HDL. All values are expressed as the mean #
SD of 3 independent experiments. RLU, relative
light units; natLDL, native low-density lipopro-
tein; natHDL, native high-density lipoprotein;
oxLDL, oxidized low-density lipoprotein; HCV,
hepatitis C virus; VSV-G, vesicular stomatitis
virus G protein; NE, no envelope; FBS, fetal
bovine serum; LPDS, lipoprotein-deficient se-
rum.
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poproteins within the tissue culture media, pseudopar-
ticles were generated and used to infect target cells in
media containing 3% lipoprotein-deficient serum. ox-
LDL reduced HCVpp infectivity in the presence and ab-
sence of bovine lipoproteins (Fig. 1C). HDL enhanced
HCVpp infection (two- to fourfold) and had no effect on
VSV-Gpp as previously reported (Fig. 1A,C).18 In the
presence of various concentrations of HDL, oxLDL was
always able to inhibit more than 95% of HCVpp infec-
tivity with the IC50 remaining at 0.5-1.5 !g/mL. How-
ever, more than 99% inhibition was only seen in the
absence of HDL (Fig. 1D). Maximal HDL enhancement
of infectivity (i.e., the ratio of the signal in the presence of
50 !g/mL HDL over the signal in the absence of HDL)
was three- to fourfold when oxLDLwas 0.4!g/mL or less
but increased to 12-fold and 79-fold when 2 !g/mL and
10 !g/mL oxLDL, respectively, were present. oxLDL in-
hibited HCVpp (clone H77) infection of different target
cells, whereas native LDL had no effect (Table 1). Prein-
cubation of HCVpp with HDL enhanced infection of
Hep3B, Huh-7, and PLC/PRF5 cells but had minimal
effect on HepG2/CD81 cells. All target cells expressed
both SR-BI and CD81 on the cell surface (data not
shown). HCVpp bearing diverse glycoproteins of geno-
type 1a (H, H77) and 1b (Con1, OH8) strains were all
inhibited by oxLDL.
Protein and Lipid Components of oxLDL Inhibit
HCVpp Infectivity and Bind to Hep3B Cells. To un-
derstand the mechanism of oxLDL inhibition of HCVpp
infectivity, we separated the protein (i.e., apolipoproteins)
and lipid fractions of oxLDL, native HDL, and oxidized
HDL (oxHDL) and evaluated their effect on HCVpp
infectivity and their ability to bind Hep3B target cells.
Both the protein and lipid fractions of oxLDL and ox-
HDL inhibited HCVpp infectivity (Fig. 2A). There was
only a minor nonspecific inhibitory effect on MLVpp
infectivity (Fig. 2B). In contrast, HDL-enhanced
HCVpp infectivity was only observed with intact HDL
particles. Because oxLDL is reported to bind SR-BI with
high affinity (Kd$4 !g/mL),26 it is feasible to hypothe-
size that it inhibits HCVpp infection in an SR-BI depen-
dent manner. Consistent with this hypothesis, we found
that oxLDL bound Hep3B cells with a similar Kd of 5.7
!g/mL (Fig. 2C). Because both apolipoprotein and lipid
moieties of oxLDL inhibited HCVpp infectivity, we were
interested to determine whether the same fractions would
Fig. 2. Target cell binding and inhibition of
HCVpp infectivity. (A) HCVpp and (B) MLVpp
infection of Hep3B in the presence of lipopro-
teins or their protein or lipid moieties. Whole
lipoproteins were used at 10 !g/mL protein
content; apolipoprotein and lipid preparations
were used at 100 !g/mL protein or phospho-
lipid, respectively. Values are expressed as the
mean # SD of 3 experiments. (C) Binding of
125I-labeled oxLDL to Hep3B cells. Values are
expressed as the mean# SD of 4 independent
experiments. (D) Binding of lipoprotein compo-
nents to target cells. Components of native and
oxidized lipoproteins were tested for their ability
to compete with 125I-oxLDL (5 !g/mL) binding
to Hep3B cells. Competitors were used in 30-
fold excess. Values are expressed as the
mean # SD of 2 independent experiments.
RLU, relative light units; n.d., not determined;
oxLDL, oxidized low-density lipoprotein; oxApoB,
oxidized apolipoprotein B; natHDL, native high-
density lipoprotein; apo, apolipoproteins; lipids;
lipoprotein derived lipid fractions; oxHDL, oxidized
high-density lipoprotein; natLDL, native low-den-
sity lipoprotein.
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compete with iodinated oxLDL binding to Hep3B cells.
Both apolipoproteins and lipid fractions of oxLDL and
oxHDL, but not lipids from native lipoproteins, com-
peted for cell binding (Fig. 2D). Thus binding to Hep3B
cells associates with the inhibition of HCVpp infectivity.
Pretreatment of Hep3B Cells With oxLDL Does
Not Inhibit HCVpp Infection. To investigate whether
oxLDL inhibits HCVpp infection by blocking a cellular
binding site, we examined the effect of preincubating
Hep3B target cells with oxLDL for 1 hour prior to virus
infection. Cells were washed and infected withHCVpp or
MLVpp (Table 2). Alternatively, pseudoparticles and ox-
LDL were mixed, incubated at 37°C for 1 hour, and then
added to the target cells. Both at 37°C or 4°C significant
HCV-specific inhibition was observed only when pseu-
doparticles and oxLDL were present on the target cell
simultaneously. Preincubation of target cells with oxLDL
had a modest effect on the luciferase signal that was indis-
tinguishable between HCVpp and MLVpp. Conversely,
HCVpp that had been allowed to bind to (but not enter)
target cells on ice for 1 hour prior to the addition of
oxLDL were still sensitive to oxLDL inhibition.
sE2 Interaction With SR-BI and CD81 Is Not
Affected by oxLDL. To determine if oxLDL directly
inhibits HCV-glycoprotein interactions with SR-BI
and/or CD81, we monitored sE2 binding to CHO cells
expressing human SR-BI, CD81, or CD9, a tetraspanin
closely related to CD81 but unable to interact with sE2.12
Anti-E2monoclonal antibodies (mAbs) could distinguish
between SR-BI–bound and CD81-bound sE2 (Fig. 3A-
B), such that monoclonal antibody 9/75 (specific for E2
amino acids 524-532) recognized sE2–SR-BI complexes
but not sE2 bound to CD81. Conversely, monoclonal
antibody 7/59 specific for the hypervariable region of E2
was able to recognize sE2–CD81 but not sE2–SRBI com-
plexes. Neither anti-E2 nor an antibody against a histi-
dine tag at the C-terminus of sE2 detected significant sE2
binding to CHO/CD9 (Fig. 3C and not shown). In nei-
ther case was the measured amount of sE2–receptor com-
plexes modulated by the presence or absence of oxLDL
(up to 50 !g/mL) or native LDL (Fig. 3D-F). Further-
more, cell surface binding of anti SR-BI was only mini-
mally affected by the presence or absence of oxLDL (data
not shown). Our data suggest that oxLDL does not sim-
ply compete with HCV for a cellular binding site but
favors a model in which entry steps subsequent to virus–
receptor binding are being perturbed and HCV–lipopro-
tein receptor ternary complexes are required for
inhibition to occur.
Silencing of SR-BI Does Not Abrogate the oxLDL
Effect. To determine whether modulation of SR-BI ex-
pression affects oxLDL inhibition of HCVpp infectivity,
Hep3B cells were transfected with siRNA against SR-BI
or CD81. Specific downregulation of the target molecules
was confirmed via flow cytometry sorting for cell surface–
expressed SR-BI and CD81 (Fig. 4A-B). While the SR-
BI–specific signal detected was only 1.5-fold above the
isotype-control signal even in cells treated with irrelevant
siRNA, its decrease to almost background in SR-BI–si-
lenced cells was reproducibly seen in independent exper-
iments (n ! 6; data not shown). Also, a loss of HDL
enhancement of HCVpp infectivity was observed in
SR-BI but not in CD81-silenced cells. Silencing CD81
clearly inhibited HCVpp infection both in the presence
and absence of HDL, whereas the effect of silencing
SR-BI on infectivity reached statistical significance only
when HDL was present. VSVGpp infectivity was not sig-
nificantly affected (Fig. 4D). The inhibitory effect of ox-
Table 1. Effect of HDL, oxLDL, and natLDL (10 !g/mL) on HCVpp Infection of Different Target Cells and HCVpp Bearing
Diverse HCV E1E2 gps
E1E2 Clone
(Genotype) Target Cell
Percent Change from Baseline
HDL oxLDL natLDL
H77 (1a)* Hep3B* %239.5# 61.3 "99.6# 0.4 %13.4# 13.6
H77 (1a) Huh-7 %151.1# 38 "99.3# 0.1 "30# 2.4
H77 (1a) PLC/PRF5 %227.4# 48.5 "98.7# 0.1 "27.1# 46.7
H77 (1a) HepG2/CD81 %67# 70.2 "92.7# 0.6 %40.9# 114.9
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
H77 (1a)* Hep3B* %326.5# 106.6 "98.3# 0.1 ND
H (1a) Hep3B %206.7# 76.7 "98.8# 0.9 ND
OH8 (1b) Hep3B %67.1# 15.6 "99.1# 0 ND
Con1 (1b) Hep3B "7.7# 27.4 "99.6# 0 ND
NOTE. Values are given as change versus values obtained in the absence of human lipoproteins (mean of n ! 3 replicates # SD).
Compared with Hep3B, the signal of strain H77 HCVpp was four-fold, six-fold, and 40-fold reduced on Huh7, PLC/PRF5, and HepG2/CD81 cells, respectively.
Compared with HCVpp of strain H, the infectivity on Hep3B cells was three-fold, five-fold, and two-fold lower for strain H77, OH8, and Con1, respectively.
Abbreviations: HDL, high-density lipoprotein; oxLDL, oxidized low-density lipoprotein; natLDL, native low-density lipoprotein; HCVpp, hepatitis C virus pseudoparticles;
ND, not determined.
*Data dealing with target cells (upper half) and E1E2 clones (lower half) were obtained using different preparations of HCVpp.
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LDL on HCVpp infectivity was maintained under all
conditions.
Interaction of HCVpp With an Oxidized Lipid
Species. Because HCV is thought to associate with #-li-
poproteins, we were interested to determine whether ox-
LDL associates with HCVpp independent of binding the
target cell. HCVpp were incubated for 1 hour at 37°C
with either a mixture of 125I-oxLDL and unlabeled ox-
LDL or an equal total amount of unlabeled oxLDL. Sub-
sequently, the mixture, pseudoparticles alone, or oxLDL
alone were subjected to sedimentation velocity centrifu-
gation over a sucrose gradient (5%-20%), and fractions
were assayed for p24 antigen to detect pseudoparticles
(Fig. 5A), infectivity (Fig. 5B), and gamma-radiation to
locate oxLDL (Fig. 5C). After centrifugation, more than
90% of the labeled oxLDL was detected in the first 2
fractions closest to the top of the gradient, independent of
the presence or absence of HCVpp. The vast majority of
p24 antigen and infectivity was located within fractions 4
through 8, with the gradient containing pseudoparticles
Fig. 3. Binding of sE2 in the presence of oxLDL. CHO cells expressing human (A) SR-BI, (B) CD81, or (C) CD9 were incubated with sE2 for 1 hour,
and bound sE2 was visualized with anti-E2 antibodies 7/59 (dashed line) and 9/75 (solid line) or an irrelevant isotype control (shaded area). (D)
sE2 binding to CHO/SR-BI in the presence (solid line) or absence (shaded area) of oxLDL (50 !g/mL) detected with anti-E2 9/75. (E) sE2 binding
to CHO/CD81 in the presence (dashed line) or absence (shaded area) of oxLDL (50 !g/mL) detected with anti-E2 7/59. (F) Mean fluorescence
intensity in the presence of increasing concentrations of oxLDL. Antibodies 9/75 and 7/59 were used for detection of sE2 in the case of CHO/SR-BI
and CHO/CD81, respectively. Max, maximum; sE2, soluble E2; oxLDL, oxidized low-density lipoprotein; CHO, Chinese hamster ovary; SR-BI, scavenger
receptor class B type I; LDL, low-density lipoprotein; irrel ab, isotype control.




Step 1 Step 2 Step 3 HCVpp MLVpp
Incubate cells with oxLDL for 1 h at 37° Wash twice Add pp to cells for 1 h at 37°C 22.1% 20.4%
Incubate cells with oxLDL for 1 h at 4° Wash twice Add pp to cells for 1 h at 4°C 26.5% 31.9%
Incubate pp with oxLDL for 1 h at 37°C — Add pp % oxLDL to cells for 1 h at 37°C 98.3% 19.3%
Incubate pp with oxLDL for 1 h at 37°C Chill to 4°C Add pp % oxLDL to cells for 1 h at 4°C 97.2%* 42.3%
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Incubate pp with oxLDL for 1 h at 37°C Chill to 4°C Add pp % oxLDL to cells for 1 h at 4°C 98.0%* ND
Incubate cells with HCVpp for 1 h at 4° Wash twice Add oxLDL to cells for 1 h at 4°C 87.1% ND
NOTE. Hep3B cells were exposed to pseudoparticles and oxLDL in the order shown. Values are given as percent of the signal obtained when performing the same
protocols without oxLDL (means of n ! 2).
Abbreviations: oxLDL, oxidized low-density lipoprotein; HCVpp, hepatitis C virus pseudoparticles; MLVpp, murine leukemia virus pseudoparticles; pp, pseudoparticles.
*Values do not match because data in top 4 and bottom 2 rows, respectively, were obtained on 2 separate occasions.
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mixed with oxLDL showing a slight shift of the p24 peak
toward a lower sedimentation velocity (Fig. 5B). This
shift was reproducibly observed in 4 independent experi-
ments andwas not seenwhenMLVppwas studied (n! 2;
data not shown). Thus, although the labeled apolipopro-
tein moiety of oxLDL andHCVpp do not appear to form
a stable interaction, there appears to be a change in the
biophysical properties of the HCVpp after exposure to
oxLDL. The infectivity of HCVpp that had been incu-
bated with oxLDL was markedly reduced, suggesting an
inactivation of viral infectivity that persists after separa-
tion of virus and oxLDL (Fig. 5C). To test this conclu-
sion, we incubatedHCVppwith oxLDL at 5!g/mL for 1
hour at 37°C, diluted the virus-lipoprotein mixture in
plain media to a point where the oxLDL concentration
was well below the IC50 and tested the infectivity of the
resulting mixture. In this case, the inhibitory effect was
reduced upon dilution, suggesting that the virus was not
irreversibly inactivated after contact with oxLDL (Fig.
5D).
oxLDL Potently Inhibits Cell Culture–Grown HCV
Particles. Finally, we assessed the effect of oxLDL on
HCVcc (J6/JFH) infection of Huh-7.5 cells.7 After 72
hours, a significant percentage of HCVcc-infected but
not mock treated cells stained positive for NS5A (Fig.
6A-B). Incubation of J6/JFH with native LDL (10 !g/
mL) for 1 hour at 37°C prior to infection had no discern-
able impact on the percentage of NS5A-positive cells in
this semiquantitative assay (Fig. 6C), whereas oxLDL (10
!g/mL) led to a marked reduction (Fig. 6D). The inhib-
itory effect of oxLDL was quantified by limiting dilution
assays in the presence of increasing amounts of oxLDL. A
dose-dependent inhibition was observed at concentra-
tions of 1!g/mL and above (Fig. 6E), suggesting a similar
potency of oxLDL for the inhibition of HCVcc and
HCVpp (Fig. 1B). In a plaque assay, oxLDL had no effect
on the titer of bovine viral diarrhea virus (strain NADL)
in MDBK cells (1.6 & 106 PFU/mL with and without
oxLDL; data not shown).
Discussion
The SR-BI ligand oxLDL demonstrates a potent and
specific inhibition of HCVpp and HCVcc infectivity
(Figs. 1, 6). An association of HCV with lipoproteins was
first reported over 10 years ago1,36; herein, we report an
inhibitory effect of a lipoprotein species on HCV. The
inhibitory effect is conserved across diverse HCV geno-
types (genotypes 1a, 1b, 2a) and for all target cells tested
(Table 1). The inhibition of the lipoprotein is most likely
exerted by an oxidized lipid species contained in oxLDL
(Fig. 2). Furthermore, we provide evidence to suggest that
inhibition does not occur through oxLDL simply acting
as a receptor antagonist (Fig. 4; Table 2) but involves a
ternary interaction of virus, receptor, and oxLDL (Figs. 2,
5; Table 2).
Other than SR-BI, the only known oxLDL receptor
expressed on Hep3B cells is CD36 (P. Balfe, personal
communication), but CD36 does not interact with sE2.14
The LDL receptor has been proposed as a possible HCV
receptor,37,38 but it recognizes only native LDL, not ox-
LDL.39,40 SR-BI was initially reported as a candidate re-
ceptor for HCV because of its ability to bind to sE2.14
Subsequent reports have shown that antibodies and
siRNA targeting SR-BI inhibit HCVpp entry15,17,41 (Fig.
4). However, this inhibition is generally modest (30%-
80%) and varies between different HCV genotypes.11,17
The anti–SR-BI monoclonal antibody used in this study
(BD anti-ClaI) and several noncommercially available an-
tisera (a kind gift fromD. Silver) failed to inhibit HCVpp
infectivity (data not shown). HDL enhancement of
HCVpp infection is clearly dependent on expression of a
functional SR-BI molecule. However, HCVpp infection,
Fig. 4. Silencing of SR-BI and CD81 in Hep3B cells. (A) Forty-eight
hours after transfection of siRNA specific for SR-BI (dashed line) or an
irrelevant control siRNA (solid line), gene knockdown was confirmed via
cell surface staining of SR-BI. Isotype control staining is indicated by the
shaded area. (B) A parallel experiment using siRNA specific for CD81
(dashed line) or irrelevant control siRNA (solid line) demonstrated re-
duced CD81 expression. (C) HCVpp infection of cells treated with the
respective siRNAs in the absence of human lipoprotein (black bars) or
presence of 10 !g/mL oxLDL (gray bars) or HDL (white bars). (D)
VSVGpp infection of siRNA-treated cells. P values indicate differences
from the analogous experiments in cells transfected with irrelevant siRNA.
Max, maximum; RLU, relative light units; SR-BI, scavenger receptor class
B type I; irr, irrelevant; siRNA, small interfering RNA.
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Fig. 5. Preincubation and subsequent sep-
aration of HCVpp and oxLDL. HCVpp, 125I-ox-
LDL, or both were incubated for 1 hour at
37°C, loaded on a 5%-20% sucrose/TRIS-
buffered saline gradient, and separated via
sedimentation velocity centrifugation. Fractions
were measured for (A) p24 antigen, (B) infec-
tivity on Hep3B cells, and (C) gamma emission.
(D) In a separate experiment, HCVpp and oxLDL
(5 !g/mL) were incubated for 1 hour at 37°C
and then diluted in media alone (gray bars) or
in media containing oxLDL (5 !g/mL) (white
bars). Infectivity values are shown relative to
HCVpp that were incubated without oxLDL and
then diluted in media (black bars). Values are
expressed as the mean# SD of 3 independent
experiments. HCVpp, HCV pseudoparticles; ox-
LDL, oxidized low-density lipoprotein; RLU, rel-
ative light units;.
Fig. 6. Inhibition of HCVcc infection by oxLDL. (A) Naı¨ve Huh-7.5 cells mock infected with supernatant from Huh-7.5 cells harboring a subgenomic
genotype 2a replicon and stained for NS5A antigen. (B,C,D) Naı¨ve Huh-7.5 infected with supernatant from Huh-7.5 harboring a full-length J6/JFH
genome. Infection was performed either (B) in the absence of human lipoproteins or in the presence of 10 !g/mL (C) native LDL or (D) oxLDL. A
representative visual field from each plate is shown. Note the 2 NS5A-positive cells near the lower margin in panel D. (E) Fifty percent tissue culture
infectious dose per milliliter of HCVcc as determined by limiting-dilution assay in the presence of increasing concentrations of oxLDL. natHDL, native
high-density lipoprotein; oxLDL, oxidized low-density lipoprotein; TCID50, 50% tissue culture infectious dose.
HEPATOLOGY, Vol. 43, No. 5, 2006 VON HAHN ET AL. 939
even in the presence of HDL, is CD81-dependent such
that CD81-negative HepG2 cells remain uninfectable in
the presence of HDL18,19 (Fig. 4 and unpublished data).
The potent inhibition of HCV cell entry via the SR-BI
ligand oxLDL supports an essential role of SR-BI in the
cell entry of HCVpp and HCVcc.
The hypothesis that oxLDL inhibits HCV infection by
interfering with virus–receptor interactions is supported
by an association between the ability of lipoprotein com-
ponents to compete with labeled oxLDL for target cell
binding (Fig. 2D) and their inhibition of HCVpp infec-
tivity (Fig. 2A). In relative terms, oxLDL was more effec-
tive in the absence of HDL, whereas, HDL enhanced
HCVpp infectivity most efficiently in the presence of
higher concentrations of oxLDL (Fig. 1D; data not
shown). The oxLDL IC50 remained unchanged in the
presence of HDL, suggesting that HDL and oxLDL may
act as noncompetitive antagonists. Preincubation of cells
with oxLDL had no inhibitory effect on their ability to
support HCVpp infection (Table 2), nor did oxLDL in-
hibit binding of sE2 to CHO cells expressing SR-BI (Fig.
3). Although sE2 may imperfectly model the behavior of
HCVpp, these data argue against oxLDL acting as a com-
petitive receptor antagonist. Rather, it may suggest that
subsequent steps of the entry process that cannot be mod-
eled using sE2 are inhibited by oxLDL. This is in keeping
with the observation that HCVpp prebound to the target
cell can still be inhibited by oxLDL (Table 2).
If oxLDL acts by interfering with the interaction be-
tween the virus and SR-BI, one could predict that its
inhibitory effect will be preserved or will be even more
pronounced when fewer receptor molecules are present.
Accordingly, when silencing SR-BI or CD81, we found
that oxLDL retained its inhibitory effect regardless of the
presence or absence of HDL and the siRNA employed
(Fig. 4). HDL enhancement of HCVpp infectivity
seemed more pronounced in CD81-silenced cells than in
cells treated with irrelevant siRNA and, as reported by
others,18,19 was abrogated when SR-BI was silenced.
However, because gene silencing is rarely complete and
few remaining molecules of a virus receptor may conceiv-
ably still suffice for virus entry, the incomplete inhibition
of HCVpp infectivity by siRNA against SR-BI cannot
rule out an involvement of this receptor.
Several lines of evidence suggest that an oxidized lipid
contained in oxLDL is the active component inhibiting
HCV cell entry: First, HCVpp are inhibited by both ox-
LDL and oxHDL, which contain common lipid species
but completely distinct apolipoprotein components (Fig.
2A). Second, the lipid fractions of oxLDL and oxHDL
inhibit HCVpp infectivity more effectively than the apo-
lipoprotein preparations, even though the latter were used
at a 10-fold higher apolipoprotein concentration com-
pared with intact oxLDL. Third, during the oxidation
process, lipids form adducts with apolipoproteins such
that apolipoprotein preparations derived from oxidized
lipoproteins may still contain lipids, whereas the lipid
fraction can be assumed to be apolipoprotein-free.42 In
keeping with this, the recognition of oxLDL by SR-BI is
thought to be mediated by an oxidized phospholipid spe-
cies.26
Although we failed to detect a physical interaction
between HCVpp and radiolabeled oxLDL (Fig. 5A,C),
we observed a change in the biophysical properties of
HCVpp after incubation with oxLDL and subsequent
separation via velocity sedimentation centrifugation
(Fig. 5A). Only the apolipoprotein moiety of oxLDL is
labeled, which may be due to an interaction of HCVpp
and a lipid component of oxLDL. However, attempts
to detect such an association using lipophilic fluores-
cent DiO as a noncovalently bound tracer failed to
show any interaction (data not shown). The infectivity
of HCVpp that had been incubated with and then
separated from oxLDL by gradient analysis was mark-
edly reduced (Fig. 5B). This suggests a direct inactiva-
tion of viral infectivity by oxLDL that persists even
after the virus and oxLDL had been separated. How-
ever, when HCVpp was incubated with oxLDL and
then diluted in media without oxLDL to a point where
the oxLDL concentration is biologically ineffective, vi-
ral infectivity was unaltered (Fig. 5D), arguing against
an irreversible inactivation of the virus. We cannot
definitively explain this difference; however, it is feasi-
ble that oxLDL-treated virus is more sensitive to inac-
tivation in the environment that it is subjected to
during sucrose gradient analysis.
We propose that oxLDL inhibition of HCVpp and
HCVcc infectivity involves a ternary interaction be-
tween virus, SR-BI, and oxLDL, requiring the simul-
taneous presence of all 3 agents. An interaction of
oxLDL with both virus and cell would maintain the
validity of the findings that show oxLDL alters the
biophysical properties of HCVpp (suggesting an inter-
action with the virus) and the association between cell
binding of lipoprotein components and inhibitory ac-
tivity (suggesting an interaction with the target cell).
However, better tools to experimentally dissect the dif-
ferent steps of the cell entry process may be required.
We may then be able to determine a more complete
pathogenesis and discover at what entry step oxLDL
inhibits HCV infectivity. Moreover, whether the same
entry routes are used by HCV in vivo remains to be
defined.
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In vivo oxLDL is generated via oxidative modification
of native LDL in the subendothelial space in a setting of
atherosclerosis (see Lusis43 for a review), and its levels are
increased in cardiovascular disease.44,45 The heteroge-
neous nature of oxLDL in vivomakes comparative studies
difficult; however, levels close to the IC50 observed in our
assay have been reported in healthy volunteers.45 An agent
capable of blocking cell entry by diverse HCV strains
would be of great clinical value in the setting of transplan-
tation for HCV-induced end-stage liver disease. Pres-
ently, outcome after transplantation is unfavorable
because of universal and rapidly progressing reinfection.46
A means of blocking HCV cell entry during the periop-
erative period might prevent reinfection of the graft. The
potency and specificity of oxLDL as well as its ability to
inactivate a broad range of HCV genotypes provide a
valuable tool. We can use this to study the molecular
mechanisms of HCV cell entry as well as develop thera-
peutics targeting the early steps in the HCV life cycle.
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